Shopping Cart 0
Cart Subtotal
AED 0

University of British Columbia - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its students. UBC offers educational services through programs such a professional programs, English language pathways, joint academic programs, exchange programs, co-operative education, innovative learning initiatives and distance education programs. The university serves adult education needs of lifelong learners by providing educational programs in UBC's Point Grey campus. It operates through peer institutions, government, non-profit and other industries for its research activities. The university operates in two campuses namely, Vancouver Campus and Okanagan Campus. UBC is headquartered in Vancouver, British Columbia, Canada

University of British Columbia-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

University of British Columbia, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

ProtoKinetix Enters into Research Agreement with University of British Columbia 12

AXIM Biotech Enters into Agreement with University of British Columbia 13

Replicel Life Sciences Enters into Agreement with University of British Columbia 14

Ritter Pharma Enters into Agreement with University of British Columbia 15

TxCell Enters into Research Agreement with University of British Columbia 16

ProtoKinetix Enters into Research Agreement with University of British Columbia 17

Sirona Biochem Enters into Research Agreement with University of British Columbia 18

Qu Biologics Enters into Research Agreement with University of British Columbia 19

InMed Pharma Enters into Agreement with University of British Columbia 20

Biommune Enters into Agreement with University of British Columbia 21

University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 22

Licensing Agreements 23

Commense Enters into Licensing Agreement with University of British Columbia 23

BirchBioMed Enters into Licensing Agreement with University of British Columbia 24

Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 25

Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26

Cangene Enters Into Licensing Agreement With University of British Columbia 27

University of British Columbia-Key Competitors 28

University of British Columbia-Key Employees 29

University of British Columbia-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 32

Corporate Communications 32

Feb 19, 2018: UBC Board of Governors elects Michael Korenberg as new chair, Sandra Cawley, new vice-chair 32

Legal and Regulatory 33

Jun 18, 2018: Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration 33

Government and Public Interest 34

Sep 11, 2018: Artificial anti-oxidant may be the next go-to supplement 34

Jul 20, 2018: The Canadian Institutes Of Health Research awards USD 5.8M Foundation Grant to Dr. Brett Finlay for his research on microbes in Health And Disease 35

Jul 10, 2018: Breakthrough discovery will change treatment for COPD patients 36

Jun 19, 2018: Alzheimer Society Research Program awards USD 2.9 million to Canadian researchers 37

Mar 27, 2018: Leading CROs Form New Industry Standards Group to Improve Collaboration with Sponsors 38

Feb 19, 2018: Government of Canada and Brain Canada announce a USD 10-million grant to establish a platform that will help researchers share data more widely and efficiently 40

Dec 20, 2017: A repurposed drug could open door to more stem cell transplants 41

Oct 03, 2017: Avon Foundation for Women (Canada) funds new breast cancer recovery trial in partnership with two Canadian universities 42

Sep 12, 2017: Alzheimer Society Research Program provides USD 3.4 million boost to dementia research 43

Aug 30, 2017: Tracing single brain cancer cells simplifies complexity of incurable brain cancers, suggesting new treatments, international study finds 44

Jul 28, 2017: UBC researchers working to engineer 'tunable' insulin production 46

Apr 24, 2017: MSFHR Funded Research Suggests Existence Of Pre-Clinical MS Symptoms 47

Feb 07, 2017: JDRF & Lilly Canada fund UBC research that could allow people with type 1 diabetes to produce their own insulin 48

Product News 49

Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 49

Jan 18, 2018: Potential new diabetes treatment being tested in Vancouver 50

Clinical Trials 51

Feb 21, 2017: OncoGenex Pharmaceuticals Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium 51

Other Significant Developments 52

Jul 04, 2018: HPV testing could be more accurate than smear tests for initial screening of cervical cancer 52

Feb 09, 2018: USD 105-million investment to make prescription medications more affordable for families 54

Jan 23, 2018: Government of Canada announces support to help reduce HIV in British Columbia 55

Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 57

Oct 17, 2017: Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery 58

Oct 13, 2017: Putting new tools in the hands of leading Canadian scientists 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

University of British Columbia, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of British Columbia, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

University of British Columbia, Pharmaceuticals & Healthcare, Key Facts 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of British Columbia, Deals By Therapy Area, 2012 to YTD 2018 9

University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProtoKinetix Enters into Research Agreement with University of British Columbia 12

AXIM Biotech Enters into Agreement with University of British Columbia 13

Replicel Life Sciences Enters into Agreement with University of British Columbia 14

Ritter Pharma Enters into Agreement with University of British Columbia 15

TxCell Enters into Research Agreement with University of British Columbia 16

ProtoKinetix Enters into Research Agreement with University of British Columbia 17

Sirona Biochem Enters into Research Agreement with University of British Columbia 18

Qu Biologics Enters into Research Agreement with University of British Columbia 19

InMed Pharma Enters into Agreement with University of British Columbia 20

Biommune Enters into Agreement with University of British Columbia 21

University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 22

Commense Enters into Licensing Agreement with University of British Columbia 23

BirchBioMed Enters into Licensing Agreement with University of British Columbia 24

Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 25

Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26

Cangene Enters Into Licensing Agreement With University of British Columbia 27

University of British Columbia, Key Competitors 28

University of British Columbia, Key Employees 29

University of British Columbia, Other Locations 30

University of British Columbia, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

University of British Columbia, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its students. UBC offers educational services through programs such a professional programs, English language pathways, joint academic programs, exchange programs, co-operative education, innovative learning initiatives and distance education programs. The university serves adult education needs of lifelong learners by providing educational programs in UBC's Point Grey campus. It operates through peer institutions, government, non-profit and other industries for its research activities. The university operates in two campuses namely, Vancouver Campus and Okanagan Campus. UBC is headquartered in Vancouver, British Columbia, Canada

University of British Columbia-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

University of British Columbia, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

ProtoKinetix Enters into Research Agreement with University of British Columbia 12

AXIM Biotech Enters into Agreement with University of British Columbia 13

Replicel Life Sciences Enters into Agreement with University of British Columbia 14

Ritter Pharma Enters into Agreement with University of British Columbia 15

TxCell Enters into Research Agreement with University of British Columbia 16

ProtoKinetix Enters into Research Agreement with University of British Columbia 17

Sirona Biochem Enters into Research Agreement with University of British Columbia 18

Qu Biologics Enters into Research Agreement with University of British Columbia 19

InMed Pharma Enters into Agreement with University of British Columbia 20

Biommune Enters into Agreement with University of British Columbia 21

University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 22

Licensing Agreements 23

Commense Enters into Licensing Agreement with University of British Columbia 23

BirchBioMed Enters into Licensing Agreement with University of British Columbia 24

Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 25

Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26

Cangene Enters Into Licensing Agreement With University of British Columbia 27

University of British Columbia-Key Competitors 28

University of British Columbia-Key Employees 29

University of British Columbia-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 32

Corporate Communications 32

Feb 19, 2018: UBC Board of Governors elects Michael Korenberg as new chair, Sandra Cawley, new vice-chair 32

Legal and Regulatory 33

Jun 18, 2018: Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration 33

Government and Public Interest 34

Sep 11, 2018: Artificial anti-oxidant may be the next go-to supplement 34

Jul 20, 2018: The Canadian Institutes Of Health Research awards USD 5.8M Foundation Grant to Dr. Brett Finlay for his research on microbes in Health And Disease 35

Jul 10, 2018: Breakthrough discovery will change treatment for COPD patients 36

Jun 19, 2018: Alzheimer Society Research Program awards USD 2.9 million to Canadian researchers 37

Mar 27, 2018: Leading CROs Form New Industry Standards Group to Improve Collaboration with Sponsors 38

Feb 19, 2018: Government of Canada and Brain Canada announce a USD 10-million grant to establish a platform that will help researchers share data more widely and efficiently 40

Dec 20, 2017: A repurposed drug could open door to more stem cell transplants 41

Oct 03, 2017: Avon Foundation for Women (Canada) funds new breast cancer recovery trial in partnership with two Canadian universities 42

Sep 12, 2017: Alzheimer Society Research Program provides USD 3.4 million boost to dementia research 43

Aug 30, 2017: Tracing single brain cancer cells simplifies complexity of incurable brain cancers, suggesting new treatments, international study finds 44

Jul 28, 2017: UBC researchers working to engineer 'tunable' insulin production 46

Apr 24, 2017: MSFHR Funded Research Suggests Existence Of Pre-Clinical MS Symptoms 47

Feb 07, 2017: JDRF & Lilly Canada fund UBC research that could allow people with type 1 diabetes to produce their own insulin 48

Product News 49

Oct 26, 2017: Vanderbilt leads international effort to develop universal flu vaccine 49

Jan 18, 2018: Potential new diabetes treatment being tested in Vancouver 50

Clinical Trials 51

Feb 21, 2017: OncoGenex Pharmaceuticals Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium 51

Other Significant Developments 52

Jul 04, 2018: HPV testing could be more accurate than smear tests for initial screening of cervical cancer 52

Feb 09, 2018: USD 105-million investment to make prescription medications more affordable for families 54

Jan 23, 2018: Government of Canada announces support to help reduce HIV in British Columbia 55

Oct 26, 2017: The Human Vaccines Project Launches New Initiative To Accelerate Development Of Universally Effective Influenza Vaccines 57

Oct 17, 2017: Scientific Update for Diabetes, Kidney Ischemia, Liver Perfusion, Retinal Cell Replacement, Monoclonal Antibody Production and Immune Cell Cryopreservation Recovery 58

Oct 13, 2017: Putting new tools in the hands of leading Canadian scientists 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

University of British Columbia, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of British Columbia, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

University of British Columbia, Pharmaceuticals & Healthcare, Key Facts 2

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

University of British Columbia, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

University of British Columbia, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

University of British Columbia, Deals By Therapy Area, 2012 to YTD 2018 9

University of British Columbia, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

ProtoKinetix Enters into Research Agreement with University of British Columbia 12

AXIM Biotech Enters into Agreement with University of British Columbia 13

Replicel Life Sciences Enters into Agreement with University of British Columbia 14

Ritter Pharma Enters into Agreement with University of British Columbia 15

TxCell Enters into Research Agreement with University of British Columbia 16

ProtoKinetix Enters into Research Agreement with University of British Columbia 17

Sirona Biochem Enters into Research Agreement with University of British Columbia 18

Qu Biologics Enters into Research Agreement with University of British Columbia 19

InMed Pharma Enters into Agreement with University of British Columbia 20

Biommune Enters into Agreement with University of British Columbia 21

University of British Columbia Enters Into Agreement With Sichuan BoXin LaiTe Biotechnology And Heracles International Investment 22

Commense Enters into Licensing Agreement with University of British Columbia 23

BirchBioMed Enters into Licensing Agreement with University of British Columbia 24

Roche Enters into Licensing Agreement with University of British Columbia and Vancouver Coastal Health Research Institute 25

Cyon Therapeutics Enters into Licensing Agreement with University of British Columbia 26

Cangene Enters Into Licensing Agreement With University of British Columbia 27

University of British Columbia, Key Competitors 28

University of British Columbia, Key Employees 29

University of British Columbia, Other Locations 30

University of British Columbia, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

University of British Columbia, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.